Top
image: AFP/Getty Images

Following regulatory win, GSK & Innoviva tout data for once-daily triple-med inhaler

September 20, 2017

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) notched a win this week after the FDA approved its once-daily, triple combination therapy for the treatment of chronic obstructive pulmonary disease. Last week, an EU agency recommended the inhaler’s approval.

Now, the companies are touting results from a late-stage trial of Trelegy Ellipta, which is composed of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta agonist.

Read More on Mass Device